Evidence map›Paper›PMID 42256247›Full record

ReviewPolymer science & technology (Washington, D.C.)2025

Advances in Nanobody-Based Platforms for Precision Cancer Diagnosis and Therapy.

Yang Yuan, Ciren Zhuoga, Chen Zeng, Wenya Zhou, Weizhi Chen, Xu Zhen, Xiqun Jiang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Polymer science & technology (Washington, D.C.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Polysaccharide-Based Encapsulation of Microbes for Enhanced Microbial Therapy.Polymer science & technology (Washington, D.C.) · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yang YuanMOE Key Laboratory of High Performance Polymer Materials and Technology, College of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210023, China.
Ciren ZhuogaMOE Key Laboratory of High Performance Polymer Materials and Technology, College of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210023, China.
Chen ZengMOE Key Laboratory of High Performance Polymer Materials and Technology, College of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210023, China.
Wenya ZhouMOE Key Laboratory of High Performance Polymer Materials and Technology, College of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210023, China.
Weizhi ChenMOE Key Laboratory of High Performance Polymer Materials and Technology, College of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210023, China.
Xu ZhenMOE Key Laboratory of High Performance Polymer Materials and Technology, College of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210023, China.ORCID https://orcid.org/0000-0003-1652-5496
Xiqun JiangMOE Key Laboratory of High Performance Polymer Materials and Technology, College of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210023, China.ORCID https://orcid.org/0000-0003-0483-0282

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanobodies, single-domain antibodies derived from camelid heavy-chain antibodies, have emerged as powerful molecular tools in cancer diagnosis and therapy due to their unique structural and functional attributes, including small size, high antigen specificity, robust stability, and ease of genetic and chemical modification. This Review provides an extensive overview of the nanobody structure, characteristics, and production methods, highlighting their advantages over conventional antibodies. We comprehensively discuss various applications of nanobodies in cancer diagnosis and therapy, encompassing their roles as antagonists or agonists in modulating oncogenic and immune-related signaling pathways, targeted delivery systems for chemotherapeutics, radionuclides, immunotoxins, and photosensitizers, and their integration into advanced imaging technologies such as PET, SPECT, and optical imaging for accurate tumor detection and monitoring. Additionally, we explore the development of innovative cell-based immunotherapies leveraging nanobody-engineered chimeric antigen receptor (CAR)-modified T cells, natural killer cells, and macrophages, illustrating their potential to enhance therapeutic precision and efficacy. Finally, we discuss the current challenges and provide perspectives on emerging nanobody technologies and their translational prospects, underscoring the potential of nanobody-based toolkits to drive next-generation precision cancer diagnostics and therapies.

Indexed as

chimeric antigen receptor-modified cell therapynanobodyprecision tumor imagingtargeted drug deliverytumor therapy

Identifiers

PMID42256247
PMCPMC13052641

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.